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Background: A wealth of published studies have been published on association between Chlamydia pneumoniae
(C.pneumoniae) infection and cerebrovascular (CV) disease, but the results were inconsistent. This meta-analysis
provides a systematic review of the available evidence from all serological and pathological studies of CV disease
and C.pneumoniae.
Methods: A comprehensive research was conducted of MEDLINE, EMBASE, CNKI, WanFang technological periodical
database and reference lists of articles to identify eligible case-control and cohort studies. Odds radio (OR) was
calculated for each study outcome. Random effect model was used as pooling method and publication bias was
estimated for the results.
Results: Fifty-two published studies that met criteria were selected. In case control studies, an association between
C.pneumoniae infection and CV disease was revealed by serum specific IgG (OR, 1.61; 95% CI: 1.34 to 1.94), serum
IgA (OR, 2.33; 95% CI: 1.76 to 3.08) and PCR technique of C.pneumoniae in peripheral blood cells (OR, 1.90; 95% CI:
1.17 to 3.07). No significant association was found in serum anti-C.pneumonae IgM seropositivity or in-situ-detection
of C.pneumoniae in arterial biopsies with CV disease. Subgroup analysis by available studies suggested that
C.pneumoniae may paly a role in atherosclerotic stroke, but be less significant in stroke of cardioembolism or other
etiologies.
Conclusion: Association between C.pneumoniae infection and CV disease depends on the analytical method adopted,
which seems stronger with stroke due to large artery atherosclerosis. Establishing a causal relationship between
C.peumoniae infection and CV disease will require more prospective studies with combination of techniques and
stratified by etiological subtypes.
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Cerebrovascular (CV) disease is one of the major causes
of long-term disability and mortality throughout the
world. Atherosclerosis is the underlying pathology respon-
sible for CV disease in developed countries and remains a
serious problem in developing nations [1]. Conventional
risk factors (eg, hypertension, diabetes, dyslipidemia and
smoking) can not completely explain the pathogenesis of
this disease and many patients, especially younger patients* Correspondence: zhumeijia1818@gmail.com
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reproduction in any medium, provided the orusually lack these risk factors. Over the past decades, in-
creasing body of evidences demonstrated that chronic
viral and bacterial infection contributes to the develop-
ment of atherosclerotic lesions [2]. C.pneumoniae is one
of the mostly implicated pathogens in this process [3-5].
C.pneumoniae, an obligate intracellular gram nega-
tive bacterium, disseminates via respiratory secretion,
causing about 10% of community-acquired pneumonia
cases and 5% of bronchitis cases [6]. A study published in
1988 firstly proposed that C.pneumoniae infection was
an avoidable cause of coronary heart disease [7]. Subse-
quently, considerable epidemiological studies implicated
C.pneumoniae in atherogenic process of CV events, basedtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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anti-phospholipids antibody formation, oxidation of LDL,
and proliferation of smooth muscle cells [4,5]. Clinical tri-
als on the clinical burden of cardiovascular disease under
the influence of antibiotic treatment have also been con-
ducted. However, these observations triggered the subse-
quent publication of several other reports with conflicting
results. More recently, a prospective cohort study have
linked the combined activity of several infections (i.e. an
infection burden), rather than single infection to stroke
risk [8]. Therefore, despite the publication of numerous
articles on the association, it remains controversial
whether C.pneumoniae is an active player or “innocent
bystander” for CV disease. Different types of study design
and various laboratory tests may largely contribute to
the disparate findings. Furthermore, the etiology of CV
disease forms is distinct, it is necessary to investigate evi-
dence of C.pneumoniae infection stratified by different
stroke etiologies.
To fill the gap, we performed for the first time this
meta-analysis of all eligible studies published before
September 2012 to clarify if there is an association
between chronic C.pneumoniae infection and CV dis-
ease risk; 2) investigate whether the association varies de-
pending on different subtypes of CV disease; 3) evaluate




We searched the MEDLINE, EMBASE, CNKI (China
National Knowledge Infrastructure) and Wanfang techno-
logical periodical database for relevant studies using the
following main MeSH heading: chlamydia pneumoniae,
chlamydophyla pneumoniae, atherosclerotic, atheroscler-
osis, stroke, cerebral ischemic, cerebrovascular, cerebral
accident, cerebral apoplexy. An upper date limit was
September 2012 and the languages were restricted to
Chinese and English. Additional references were iden-
tified by reviewing the bibliographies of retrieved arti-
cles. After an initial screening of titles and abstracts,
only relevant articles remained. The full text of these
publications was read to decide whether needed infor-
mation on the topic of interest was included.
Inclusion criteria
Articles were eligible if they met the following criteria:
1) the study evaluated the relation between C.pneumo-
niae infection and CV disease (defined as any fatal or
non-fatal ischemic stroke,hemorrhagic stroke or transi-
ent ischemic attack); 2) the study had a (nested) case-
control or cohort design; 3)validated testing tool(s) for
detecting C.pneumoniae was used; 4) they reported risk
estimate with 95% confidence interval (CI) or providedsufficient information to calculate. When more than one
of the same patient population was included in several
publications, only the most recent or complete study
was included. No quality scoring was attempted, since
the scoring in meta-analyses of observational studies is
controversial and has not been internationally accepted to
date [9]. Two investigators (Juan Chen and Meijia Zhu)
independently selected studies and discrepancies were re-
solved by consensus.
Data extraction
For eligible study, the following information was ex-
tracted independently by two researchers: first author’s
name, publication year and country, study design type,
average patient characteristics (age and male proportion
of cases) within each study, assay methods of C.pneumo-
niae infection, fully adjusted risk estimate with the cor-
responding 95% CI and the adjustment for the main
confounding factors. For studies in which risk estimates
were reported for more than one set of adjustments, the
most adjusted estimate was used. For the studies in
which only the number of participants was presented,
the unadjusted risk estimates and 95% CIs were calcu-
lated. For the sero-epidemiological studies using micro-
immunofluorescence (MIF) as test method, the criterion
for the antibody cut-off point titer was 1/16 or higher.
Statistical analysis
We present this meta-analysis following the Meta-analysis
of Observational Studies in Epidemiology (MOOSE) state-
ment [9]. The risk estimate as well as its lower and upper
CIs were log transformed for odds ratios before conduct-
ing the analyses. The pooled value for the effect size (odds
radio) was calculated by use of a random effect model
using the method of DerSimonian & Laird [10]. Since het-
erogeneity could be present as the result of the variety of
studies included. Heterogeneity was assessed with the use
of the Q statistic, inconsistency index (I2), taking values in
the range 0 ~ 100%, whereas p-value < 0.05 or I2 > 50%
were considered as significant heterogeneity. We per-
formed a subgroup analysis to assess the ORs in patients
with stroke of different subtypes according to Trial of
Org 10172 in Acute Stroke Treatment (TOAST) criteria.
Meta-regression with restricted maximum likelihood
(REML) was performed to explore the potentially import-
ant covariates: age (mean age in participants) and sex
(proportion of males in cases), with the dependent vari-
able being the natural logarithm of the OR from each
study. Publication bias was evaluated using funnel plot,
Egger’s regression and Begger’s method. In the presence
of publication bias, the non-parametric “trim and fill”
method of Duval and Tweedie [11] was applied as a type
of sensitivity analysis in order to assess the potential influ-
ence of missing studies (if any). All statistical analyses
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College Station, TX). Statistical significance was defined at
p value < 0.05.
Results
Identified studies
Our search initially identified 1151 unique citations, of
which the majority were excluded after the first screen-
ing of titles and abstracts, and mainly because they were
reviews, case-reports, letters or irrelevant to our analysis.
After assessing full text of potentially relevant articles,
52 studies published between 1996 and 2012 were en-
rolled [3-5,8,12-59], comprising 50 (nested) case-control
studies and 2 prospective cohort studies. Figure 1 shows
a flow diagram describing the study selection process.
The majority of studies matched regarding various
population characteristics and maximally adjusted esti-
mates from studies were used instead of the raw data
or unadjusted ones in some of included studies. The
classification of the material was based on the allow-
able methods of measurement: polymerase chain reaction
(PCR) technique, serum antibodies or immunohistochem-
ical method (IHC) against C.pneumoniae. Most of the
studies detected serum antibody to define C.pneumoniae
infection and report summary statistics, as 12 studies used
PCR in peripheral blood cells or IHC in carotid biopsies
for validating C.pneumoniae detection. Table 1 and 2
demonstrate the main characteristics of these studies.Figure 1 Flow diagram of the study-selection process.Determination of anti-C.pneumoniae IgG in serum
Forty-two studies – thirty-six cross-sectional, five nested
case control studies and one cohort study – compared the
association of CV disease group versus control groups
with serum anti-C.pneumoniae IgG titers. The number of
CV cases in the case–control studies ranged from 18 to
483, with a total of 4240; while the number of subjects in
control groups ranged from 15 to 483, with a total of
7493. The overall estimated OR of case–control studies
based on random effect was 1.61 (95% CI, 1.34 to 1.94;
p = 0.00) and the cross-sectional studies demonstrated
a more significant positive association with OR = 1.74
(95% CI, 1.43 to 2.10; p = 0.00). The Q statistic suggested
an excessive heterogeneity between case–control studies
(p, 0.00), with I2 = 65.9%. Furthermore, sensitivity analysis
showed that the results were not affected by sequential
exclusion of any particular study. No available methods
favored the presence of publication bias. The Begger’s test
yielded a P-value of 0.83 (zc = 1.58) and the Egger’s fixed
effects regression suggested a marginally significant evi-
dence for publication bias (t = 2.12; p = 0.04). Forest
plot was shown in Figure 2. Funnel plot was shown
in Figure 3. Considering the result yielded by Egger’s
test, we had to conclude that the hypothesis of publi-
cation bias could not be further considered as valid.
Applying“trim and fill” method to evaluate publication
bias obtained a corrected OR = 1.62 (95% CI :1.34 to
1.95; p = 0.00), which suggested correction for potential
Table 1 Characteristic of serological studies











Bandaru VC 2012 India CSCC 100/100 Ischemic stroke MIF IgA, IgG Age, gender, diabetes, smoking,
hypercholesterolemia,
hyperhomocysteinemia.
Hasan ZN 2011 Iraq CSCC 50/40 Ischemic stroke ELISA IgA, IgG None
Kēnina V 2011 Latvija CSCC 102/48 Ischemic stroke ELISA IgG None
Chen YJ 2010 China CSCC 50/50 Ischemic stroke MIF IgG None
Bandaru VC 2009 India CSCC 120/120 Ischemic stroke MIF IgA, IgG None
Bandaru VC 2009 India CSCC 120/120 Ischemic stroke MIF IgA, IgG None
Tiszlavicz Z 2009 Hungary CSCC 280/150 Ischemic stroke ELISA IgG None
Alavi SM 2009 Iran CSCC 45/45 Ischemic stroke ELISA IgG None
Bandaru VC 2008 India CSCC 200/200 Ischemic stroke MIF IgA, IgG Age, diabetes, smoking, alcoholics,
hypertension, hyperhomocystenemia,
hypercholestemia.
Lin TM 2008 China CSCC 450/450 Ischemic stroke MIF IgG Gender, hypertension, diabetes,
hypercholesterolemia, and smoking.
Hu J 2008 China CSCC 100/60 Ischemic stroke,
TIA
ELISA IgG None
Kis Z 2007 Hungary CSCC 59/52 Ischemic stroke ELISA IgA, IgG Age, gender
Alamowitch S 2007 France CSCC 483/483 Ischemic stroke MIF IgA, IgG Diabetes, smoking, hypertension, total
cholesterol, CHD, season of enrolment.
Piechowski JB 2007 Poland CSCC 94/103 Ischemic stroke ELISA IgA, IgG Age and gender
Chi LQ 2007 China CSCC 50/48 Ischemic stroke ELISA IgG None
Liu JX 2006 China CSCC 47/48 Ischemic stroke ELISA IgG None
Njamnshi AK 2006 Cameroon CSCC 64/64 Ischemic stroke,
TIA
MIF IgA, IgG Diabetes, smoking, hypertension,
obesity and alcohol intake.
Elkind MS 2006 USA CSCC 239/428 Ischemic stroke MIF IgA, IgG Age, gender, diabetes, smoking, atrial
fibrillation, hypertension, HDL, LDL and
race.
Chen L 2006 China CSCC 135/135 Ischemic stroke ELISA IgG None
Liu AM 2006 China CSCC 80/80 Stroke MIF IgA, IgG None
Zhou B 2005 China CSCC 76/80 Ischemic stroke EIA IgA Age, gender, smoking, alcohol intake,
body weight, hypertension,
cholesterol, hypertention.
Johsen SP 2005 Denmark NCC 254/254 Ischemic stroke ELISA IgA, IgG Diabetes, smoking, hypertension,
cholesterol, BMI, alcohol intake, and
education.
Li FL 2004 China CSCC 65/25 Stroke ELISA IgA, IgG, IgM None
Anzini A 2004 Italy CSCC 141/192 Ischemic stroke MIF IgA, IgG,
IgM
Age, gender, CV risk factors and
socioeconomic status.
Manuela V 2004 Netherlands CSCC 41/55 Ischemic stroke ELISA IgA, IgG Smoking, hypertension and
hypercholesterolemia.
Apfalter P 2004 Australia CSCC 45/30 Stroke, TIA MIF IgA, IgG, IgM None
Carusone CS 2004 Canada CSCC 28/24 Stroke MIF IgA, IgG Age, gender and smoking.
Bucurescu G 2003 USA CSCC 25/25 Stroke, TIA MIF IgA, IgG None
Ngeh J 2003 UK CSCC 100/87 Stroke, TIA ELISA IgA, IgG,
IgM
Age, gender, smoking, diabetes,
hypertension, CHD.
Kawamoto R 2003 Japan CSCC 40/85 Ischemic stroke ELISA IgG None
Sirmatel F 2003 Turkey CSCC 26/53 Ischemic stroke MIF IgG None
Zou R 2003 China CSCC 112/50 Stroke ELISA IgM, IgG None
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Table 1 Characteristic of serological studies (Continued)
Wolf SC 2003 Germany CSCC 30/116 Ischemic stroke ELISA IgA, IgG Age, gender, diabetes, match for other
risks factors.
Sessa R 2003 Italy CSCC 18/33 Ischemic stroke,TIA MIF IgA, IgG None
Smiega M 2003 Canada NCC 107/3061 Stroke MIF IgA ,IgG Age, gender, diabetes, smoking,
hypertension, and hypercholesterolemia.
Tanne D 2003 Israel NCC 134/134 Ischemic stroke ELISA IgA, IgG Diabetes, smoking, BMI, hypertension.
Katie A C 2003 Australia PC 119/1493 Stroke MIF IgA, IgG Age, gender, diabetes, smoking, BMI,
hypertension, cholesterol, TG,
hemoglobin and systolic blood pressure.
Gerdes v 2002 Netherlands NCC 26/273 Ischemic stroke ELISA IgA, IgG None
Madre JG 2002 Spain CSCC 91/112 Ischemic stroke MIF IgA None
Tarnacka B 2002 Poland CSCC 20/15 Sympotomatic
carotid disease
ELISA IgG None





Katsenis C 2001 Greece CSCC 20/15 Sympotomatic
carotid disease
ELISA IgM None
Elkind MS 2000 USA CSCC 89/89 Ischemic stroke MIF IgA, IgG Diabetes, smoking, hypertension, HDL,
education, match for age, gender, race.
Glader CA 1999 Sweden NCC 97/197 Ischemic stroke MIF IgA, IgG Diabetes, smoking, BMI, hypertension,
hypercholesterolmia.
Wimmer MLJ 1996 Germany CSCC 58/52 Ischemic stroke,TIA MIF IgA, IgG Age, gender, hypertension, migraine.
CSCC, cross-sectional case control; NCC, nested case control; PC, prospective case–control or cohort; ELISA, enzyme-linked immunosorbent assay;
MIF, microimmunonuorescence; HDL ,high density lipoprotein; LDL, low density lipoprotein;TG, triglycerides; CHD, coronary heart disease; BMI, body mass index;
TIA, transient ischemic attack; CV, cerebrovascular.
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risk estimate. The one and only cohort study by Katie
AC et al., with sample size of 1612 cases, which was
not enrolled in this pooled analysis, reported an RR = 0.88
(95% CI: 0.52 to 1.47).Table 2 Characteristic of studies using PCR or IHC





Gagliardi RJ 2009 Brazil CSCC 52/59 Ischemic stro
Kis Z 2007 Hungary CSCC 59/52 Ischemic stro
Apfalter P 2004 Australia CSCC 45/30 Stroke, TIA
Wang SL 2003 China CSCC 93/90 Ischemic stor
Müller J 2003 Denmark CSCC 193/368 Stroke
Sessa R 2003 Italy CSCC 18/33 Ischemic stro
Wohlschlaeger J 2005 German CSCC 9/23 Ischemic stro
Sessa R 2003 Italy CSCC 18/33 Ischemic stro
Katsenis C 2001 Greece CSCC 20/15 Sympotomati
LaBiche R 2001 USA CSCC 37/57 Sympotomati
Wohlschlaeger J 2005 German CSCC 9/23 Ischemic stro
Lastas A 2004 Lithuania CSCC 141/59 Sympotomati
Neureiter D 2003 German CSCC 20/40 Ischemic stro
Jahromi BS 2003 Canada CSCC 57/13 Stoke,TIA
CSCC, cross-sectional case control; PCR, polymerase chain reaction; TIA, transient isc
mononuclear cell.Determination of anti-C.pneumoniae IgA in serum
Thirty-one publications reported data on the association
of C.pneumoniae infection and CV disease based on
anti-C.pneumoniae IgA sero-positivity. The number of




ke, TIA PCR PBMC/DNA 0.37(0.01 ~ 9.32)
ke PCR PBMC/DNA 1.92(0.61 ~ 6.01)
PCR PBMC/DNA 0.65(0.09 ~ 4.89)
ke PCR PBMC/DNA 2.29(1.26 ~ 4.13)
PCR PBMC/DNA 1.35(0.74 ~ 2.46)
ke,TIA PCR PBMC/DNA 5.98(1.68 ~ 21.31)
ke PCR Carotid plaque/DNA 2.75(0.15 ~ 49.36)
ke,TIA PCR Carotid plaque/DNA 1.84(0.56 ~ 6.05)
c carotid disease PCR Carotid plaque/DNA 4.19(0.19 ~ 93.97)
c carotid disease PCR Carotid plaque/DNA 0.83(0.26 ~ 2.72)
ke IHC Carotid plaque 0.14(0.01 ~ 1.27)
c carotid disease IHC Carotid plaque 0.88(0.33 ~ 2.38)
ke IHC Carotid plaque 9.0(2.32 ~ 34.88)
IHC Carotid plaque 0.6(0.18 ~ 2.07)
hemic attack; IHC, immunohistochemical method; PBMC, peripherial blood
Figure 2 Forest plot on the random-effects of CV disease associated with C.pneumoniae infection by IgG seropositivity.
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control groups ranged from 25 to 483, with a total of
6759. With random effect model, C.pneumoniae infec-
tion was statistically associated with an increased risk of
CV events in twenty-nine case–control studies (OR, 2.33;
95% CI: 1.76 to 3.08; p = 0.00), and the cross-sectional
studies demonstrated a summary OR = 2.87 (95% CI: 2.11
to 3.91; p = 0.00). The heterogeneity between all case–
control studies was substantial (p = 0.00; I2 = 70.9%). Fur-
thermore, we observed the result was not affected byexclusion of any specific study from the pooled analysis.
Forest plot was shown in Figure 4. Besides, Begger’s
(zc = 2.55; p = 0.01) and Egger’s test (t = 3.15; p = 0.00)
indicated presence of publication bias among those
studies. The shape of the funnel plot did reveal some
asymmetry (Figure 3). The adjusted pooled estimates
by“trim and fill”method was OR 2.33 (95% CI: 1.76 ~
3.08; p = 0.00), which suggested missing publications
did not materially alter the combined risk estimate.
The two prospective cohort studies were not included
Figure 4 Forest plot on the random-effects of CV disease associated with C.pneumoniae infection by IgA seropositivity.
Figure 3 Funnel plots for publication bias detection.
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Figure 5 Forest plots on the random-effects of CV disease associated with C.pneumoniae infection on IgM seropositivity, PCR and
IHC methods.
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with a size of 1625, showed a positive relationship
with RR = 1.30 while the other cohort study (Katie
AC et al.) obtained RR = 0.67, suggesting a combined
estimate effects on the association between C.pneuno-
niae infection with CV disease.
Determination of serum anti-C.pneumoniae IgM
Serum anti-C.pneumoniae IgM titers were measured in
six sero-epidemiologic case–control studies. The num-
ber of CV cases in the studies ranged from 20 to 141,
with a total of 519; while the number of subjects of con-
trol groups ranged from 15 to 192, with a total of 454.
The pooled estimate was 1.02 (95% CI: 0.47 to 2.24;
p = 0.90). No significant heterogeneity was found among
the six studies (p = 0.36; I2 = 8.5%).The Begger’s (zc = 0.00;
p = 1.00) and Egger’s tests (t = 0.54; p = 0.62) suggested no
publication bias, which were in accordance with the fun-
nel plot. The forest plot was shown in Figure 5 and funnel
plot was shown in Figure 3.
PCR Detection of C.pneumoniae in PBMC
In six case–control studies, the peripheral blood cells
were collected to detect C.pneumoniae DNA by PCR
technique. The size of case groups ranged from 18 to
193, with a total of 460; while the size of control
groups ranged from 30 to 368, with a total of 632.
The overall OR for the association of C.pneumoniaewith CV disease based on DNA detection was esti-
mated to be 1.90 (95% CI: 1.17 to 3.07; p = 0.01). The
homogeneity was observed among six studies (p = 0.24;
I2 = 25.8%).The Begger’s (zc = 0.00; p = 1.00) and Egger’s
tests (t = −0.35; p = 0.74) did not show any publication
bias, and asymmetry did not occur in the funnel plot.
The forest plot was shown in Figure 5. Funnel plot
was shown in Figure 3.
PCR detection of C.pneumoniae in carotid biopsies
There were four studies using PCR to detect the bacter-
ium in carotid samples. The total number of samples in
case groups was 84 and the number in control groups
was 128. One by Katsenis et al., which obtained the
highest OR had the lowest weighting, followed by study
by Wohlschlaeger et al. Taken together, the studies re-
ported an OR of 1.41 (95% CI: 0.65 to 3.06; p = 0.39),
providing no evidence for a statistically significant asso-
ciation between CV disease and C.pneumoniae expos-
ure. The studies were homogeneous among the studies
(p = 0.64; I2 = 0.0%). The Begger’s and Egger’s test sup-
ported that the publication bias unlikely (zc = 1.02, p =
0.31; t = 1.34, p = 0.31). The forest plot was shown in
Figure 5. Funnel plot was shown in Figure 3.
Immunohistochemical studies
Four studies, included 227 total events of CV disease
and 227 control cases, detected the C.pneumoniae
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eiter et al. obtained the highest OR. There was no evi-
dence to support that C.pneumoniae in carotid
plaque contributed the CV disease (OR, 1.06; 95% CI:
0.25 to 4.47; p = 0.93). The Q test yields a significant
P-value of 0.00, suggesting a significant heterogeneity
with I2 = 77.1%. Moreover, sensitivity analysis showed
that the exclusion of any study did not alter the
pooled result. Neither the Begger’s (zc = 0.34; p = 0.73)
nor the Egger’s test (t = −0.31; p = 0.79) showed any publi-
cation bias. The forest plot was shown in Figure 5. Funnel
plot was shown in Figure 3.
Subgroup analysis
There have been some serological studies reporting the
results by etiological subtypes of stroke(TOAST criteria:
large artery atherosclerosis, cardioembolism, small artery
occlusion, other or undefined etiology). In order to
exclude the influence of different study methods, the
research carried out subanalysis of association between
C.pneumoniae infection and CV disease on seropositivity
of IgG and IgA , respectively.
Seven studies on seropositivity of anti-C.pneumoniae
IgG were included. Subanalysis showed a positive statisti-
cally significant result for the CV cases with large artery
disease versus the control (OR, 1.91; 95% CI: 0.92 to 3.97;
p = 0.08) ,which was much more significant than ischemic
stroke of other etiologies: for cardioembolism(OR, 1.87;
95% CI: 0.59 to 5.97; p = 0.29), for small artery occlusion
(OR = 1.01; 95% CI: 0.63 ~ 1.64; p = 0.96); for other eti-
ology (OR, 0.80; 95% CI: 0.23 to 2.72; p = 0.72) and for un-
defined etiology (OR, 1.52; 95% CI: 0.69 ~ 3.33; p = 0.30).
There were five research reports dedicating the rela-
tionships between seropositivity of anti-C.pneumoniae
IgA and stroke by TOAST criteria. Subanalysis of these
studies suggested the advanced OR in large artery ath-
erosclerosis versus control was 2.25 (95% CI: 1.12 to
4.51; p = 0.02), which was much more significant than
cardioembolism groups (OR, 1.58; 95% CI: 0.92 to 2.72;
p = 0.10), small artery occlusion (OR, 0.77; 95% CI: 0.21
to 2.92; p = 0.71), other etiology (OR, 1.07; 95% CI: 0.43
to 2.68; p = 0.88) or the undefined etiology (OR, 1.89;
95% CI: 0.61 to 5.88; p = 0.27).
In one study (Neureiter D etc.) using IHC to detect
C.pneumoniae infection, all the cases suffered from is-
chemic stroke of large artery-atherosclerosis according to
the TOAST criteria, and it showed a significant associ-
ation with OR = 9.0. The studies detecting C.pneumoniae
infection based on serum IgM or by PCR did not investi-
gate the association by stroke subtypes.
Meta-regression on study-level covariates
In an attempt to explain the large amount of heterogen-
eity in the sero-epidemiological results, meta-regressionwas applied, where we attempted to use as explanatory
variables, various study-level covariates. We finally con-
sidered two potential covariates: proportion of males in
cases and the mean age of cases. Unfortunately, multi-
variate regression demonstrated no significant between
the two moderators and only bits of ORs heterogeneity
originates from the different age and male percents in
each study.
Discussion
The notion that C.pneumoniae infection may be re-
sponsible for atherosclerosis and vascular accidents is
not new. Previous meta-analysis just addressed the as-
sociation between C.pneumoniae and coronary artery dis-
ease (CAD) or atherosclerosis based on sero-epidemiologic
studies [60]. Even though CV disease shares many risk
factors with CAD because of the underlying athero-
sclerotic mechanism, it was much more heterogeneous
for the comprehensive manifestation and multifactorial
etiology. Large amount of studies have identified an appar-
ent linkage between C.pneumoniae infection and CV acci-
dents, as several studies failed to demonstrate consistent
associations. The present study was promoted for the ab-
sence of any published meta-analysis on the association
between C.pneumoniae infection and CV disease. In con-
sideration of the diversity of laboratorial methods and in-
terpretative criteria, we enrolled all available studies to
date using different markers of chronic C.pneumoniae in-
fection rather than sero-epidemiological studies only to
evaluate the relationship point to point.
Antibody investigation
Serum antibody detection is the most commonly used
assay to diagnose acute or chronic C.pneumoniae infec-
tion, including the markers: IgG, IgA and IgM. Each type
of immunoglobin has the specific kinetic feature. In pri-
mary infection patients, IgM antibody appears about 2
to 3 weeks after the onset of infection and is generally
undetectable after 2 to 6 month in serum. IgG antibody
does not reach high title until 6 weeks after the onset of
illness, with a half-life of weeks to months. In case of re-
infection, IgM antibody may not appear and the level of
IgG titer increase within a week [61]. Thus, the isolated el-
evated IgG can only be interpreted as a previous antigenic
contact and past infection, with the exception of IgG ele-
vation between two samples or an especially high level in
one sample represents a current infection, whereas IgM
may not be detectable in specimens in early course of
illness or reinfection. IgA has a biological half-life less
than 7 days and the presence has been associated with
current or chronic infection. Although debated, high
IgA titres has been suggested to be a more valid and
reliable measure of chronic active infection compared
with IgG [18].
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MIF to detect IgG, IgA or IgM, with the titer cutoff
points of 1/16 or higher by MIF. In the meta-analysis of
case–control studies, the elevated titer of IgA or IgG
showed a significant relationship with CV disease, while
the IgM did not. These findings are consistent with
reports that most people have antigenic contact with
C.penumoniae early in their lives and that re-infections
are the norm, accounting for the absence of IgM in re-
infection [62]. There were only two prospective cohort
studies published to date evaluating the relation between
C.pneumoniae infection and CV disease, while one used
ELISA and the other one used MIF as detecting method,
obtaining contradictory results by IgA and a negative
result by IgG. In general, prospective cohort studies are
considered superior to case–control and cross-sectional
studies, since prospective studies investigate temporal
relations and can indicate whether the exposure variable
preceded the outcome variable. In contrast, in cross-
sectional studies, the potentially causal exposure variable
and the outcome variable are determined at the same or
close moment, which makes it difficult to distinguish be-
tween them, since pneumonia is the most common post-
stroke infection, which mostly occur in acute phase of
stroke [63]. Nevertheless, if participants in prospective
studies are infected in the period between blood collection
and stroke manifestation, the exposure status will also be
misclassified, which leads to excessively underestimation
of the relation. After all, despite the statistical significance
of the positive association between C.pneumoniae and CV
disease, its causal relevance to CV disease remains uncer-
tain for inadequate literature amount of prospective co-
hort studies.
PCR studies in PBMC
Recently, C.pneumoniae DNA detection by PCR tech-
nique has been shown to be a valid diagnostic method
and apparently more reliable than other methods.
C.pneumoniae may localize in atheromatous cardio-
vascular tissues, peripheral blood monocytes and ather-
omatous lesions of arteries [52,56]. These organisms and
positive monocytes may contribute to total antibody
production. PCR test allows the active current infec-
tion diagnosis, being negative for the patients previously
contaminated and already healed. The presence of circu-
lating DNA of C.pneumoniae may represent a persistent
systemic infection, but this method must be performed
with great caution to prevent false-positive and false-
negative results. Our evaluation of studies with PCR of
PBMC showed that C.pneumoniae DNA confers an odds
ratio for CV disease of approximately 1.90 (95% CI:1.17 to
3.07) and the results of the five studies were homologous.
The significant results from sero-epidemiological studies
and PCR detection in PMBC all contribute to thehypothesis that a common secondary C.pneumoniae in-
fection eventually leading to atheroma formation and
plaque rupture, which is in accordance with previous
studies [64].
Tissue diagnosis by PCR and IHC
C.pneumoniae can directly infected cells of vessel wall,
leading to latent residence infection. That is why the
DNA and antibody of the pathogen has been identified
in atheromatous tissues by use of various methods [4].
The pooled analysis of four studies with PCR on carotid
plaque biopsy showed a combined OR, suggesting no
significant difference in the prevalence of C.pneumoniae
infection between cases and controls. IHC offers the ad-
vantage of preserving tissue morphology and permitting
localization of the infectious agent to specific areas and
tissues. In the four studies using IHC as detecting
method, only one showed a strong relationship with a
high OR = 9.0. Despite this, no significant relationship
was found by pooled analysis (OR = 1.06). The discrep-
ancy between the results from peripheral blood and
atheromatous plaques may be attributed to several fac-
tors. Wohlschlaeger J etc. evaluated different cerebral
aortic biopsy in patients with CV disease and observed
the highest C.peneumoniae prevalence using PCR in
right cerebral vascular artery (20%), and lower in carotid
artery (11.1%) or basilar artery (10%). What’s more, by
IHC, they observed the highest prevalence in the basilar
artery (30%) and right middle cerebral artery (30%), but
lowest in the carotid artery (11.1%) [56]. Thus, it is ques-
tionable if bare signals observed from carotid samples
reflect systematically the authentic condition of the pa-
tients. Another explanation is the fact that both patients
with CV disease and control subjects was atheroscler-
osis, the only difference was whether they were symp-
tomatic. Part of the control subjects have undergone
carotid endarterectomy are liable to have advanced ath-
erosclerosis and at the highest risk of current CV events.
After all, the lack of a true gold standard of PCR or IHC
technique to date makes it difficult to assess these methods.
A recent study, in which C.pneumoniae seroconversion
assay and PCR methods were evaluated for diagnosis of
C.pneumoniae infection during an outbreak in a military
community, suggested that the sensitivity of PCR was
lower than that of serologic antibody testing [65].
Association by subgroups of strokes
Stroke is a disease of different etiologies (i.e., large artery
disease, cardioembolism or small vessel disease). Investi-
gations in etiological subtypes of ischemic stroke may
help to clarify the possible role of C.pneumoniae in CV
disease, which has only been addressed in studies of
small sample size. Previous studies indicated that se-
ropositivity to C.pneumoniae is strongest in patients
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tributes to 10 ~ 20% of strokes, as defined in Acute
Stroke Treatment (TOAST) criteria, but less frequent
in patients with a stroke due to small-vessel occlusion
[66]. In our meta-analysis, this issue was confirmed by
seropositivity of IgG and IgA, which is consistent with
the hypothesis that C.pneumoniae contributes to athero-
sclerosis. One of in-situ studies using IHC technique
researched the relation by large artery atherosclerosis, and
strengthened the relation more [57]. Furthermore, the re-
sults also suggested C.pneumoniae might be effective in
cardioembolism by elevated serum IgG (OR = 1.87) as well
as IgA (OR = 1.58), which deserve more investigation
in future studies. Because stroke of cardioembolism
results from coronary atherosclerosis in many cases,
it is plausible that these patients would also be asso-
ciated with C.pneumoniae infection. The issue whether
C.pneumoniae infection promotes stroke of small vessel
disease or other etiology remains questionable for inad-
equate sample size.
The development of atherosclerotic CV disease in-
volves a series of steps: initiation, progression, plaque
formation, plaque rupture or erosions, and thrombosis.
Compelling data indicate that C.pneumoniae infection
does contribute to the latter stage of carotid atheroscler-
osis instead of the earlier stage, since it might promote
atherogenesis and eventually trigger acute cardiovascular
events [64,67]. Some studies also suggested patients in-
fected within a week before the onset of stroke were
more likely to develop cerebral infarcts [68]. The patho-
gen may gain access to the vasculature during local in-
fection and exacerbate atherosclerosis either directly or
indirectly. Direct effects include cell lysis, lipid oxidiza-
tion and proliferation of smooth muscle cells. Indirect
systematic effects may involve induction of acute phase
proteins expression, establishment of a prothrombotic
state and promotion arteriosclerosis by activating mono-
cytes [69,70]. Furthermore, C.pneumoniae was suggested
to trigger specific cell-mediated immunity within plaques
and promote plaques rupture by enhancing the produc-
tion of matrix-degrading metalloproteinase, which was
considered to be responsible for fibrous cap rupture [71].
Activated immune cells also produced cytokines and cyto-
toxic antibodies, which in turn, lead to the local per-
petuation of the vessel wall damage. Further researchers
proposed the bacterium act in cooperation with con-
ventional risk factors and genetic predisposition, which
insufficient for disease generation alone [56]. Therefore,
whether a specific pathogen will initiate or accelerate the
complications of atherosclerosis maybe determined by the
complex interactions of those complex factors. It would
thus appear that further research will be needed before we
can predict how C.pneumoniae influence atherogenesis
and its potential interaction with other pathogenic factors.The major strength of our meta-analysis is that we
enrolled all available cross-sectional and prospective
studies using various detection methods, which en-
hanced comprehensiveness of the findings and reduced
the likelihood of selection bias. However, several limita-
tions should be acknowledged. First, at present, the as-
sessment of chronic active C.pneumoniae infection is
difficult and there is no wholly satisfactory method for
diagnosis. In this meta-analysis, we defined the diag-
nosis standard in various approach according to the rec-
ommendations from the Centers for Disease Control and
Prevention and the Laboratory Centre for Disease Control
[61]. Second, heterogeneity in sero-epidemiological studies
is substantial. The variability in serum sample dilutions
and in the method used by commercial laboratories may
partially account for this heterogeneity. It is also recog-
nized that cross-reactivity between C.pneumoniae and
other micro-organism may occur in serology. Other pos-
sible explanations include small sample sizes, degree of
the results adjustment, time of blood collection and stage
of the CV disease. In addition, prospective studies typically
can provide more information on the clinical relevance.
Regrettably, only two prospective cohort studies investi-
gated CV disease were eligible and yielded contradictory
results, thus insufficient to demonstrate a causal relation-
ship on this issue.
Conclusions
In the present meta-analysis, seropositivity for anti-C.
pneumoniae IgG, IgA and C.pneumoniae DNA were
found significantly associated with increased CV disease
in case–control studies, and the serum IgM was not.
Meanwhile, data from the present study did not show a
significant correlation between CV disease and in-situ
detection of C.pneumoniae in arteries specimens. Thus,
the finding or not of an association depends on the
method employed. In addition, sub-analysis of available
studies showed C.pneumoniae is strongest associated
with patients with strokes of large artery atherosclerosis,
but less frequent in patients with a stroke due to cardi-
oembolism and no clear association were found for other
types of ischemic stroke. In conclusion, assessment of dif-
ferent microbiological technique methods and more pro-
spective cohort studies about various stroke subtypes are
needed in future to confirm the causal relationship be-
tween C.pneumoniae infection and CV disease.
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